Business Context and Reporting Period
This Form 6-K filing covers the period ending June 30, 2004, for GlaxoSmithKline plc. The document primarily reports on share repurchase activities authorized by shareholders at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests in company shares during late June 2004.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks and treasury holdings.
- Share Repurchases: The Company purchased a total of 2,505,000 Ordinary Shares between June 23 and June 29, 2004.
- Repurchase Prices: Prices ranged from 1,139.57 pence to 1,164.32 pence per share.
- Treasury Shares: Following the final transaction on June 29, the Company held 26,418,000 shares in treasury.
- Shares in Issue: Excluding treasury shares, 5,907,383,837 shares were in issue as of June 29, 2004.
Material Changes
The primary material change reported is the reduction in outstanding shares due to the treasury buyback program. The number of shares in issue decreased from 5,910,185,657 on June 23 to 5,907,383,837 on June 29. Additionally, the filing details minor changes in directors' beneficial interests through the GlaxoSmithKline Employee Trust, the US Retirement Savings Plan, and Personal Equity Plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of corporate actions and director shareholdings.
Investor Verification Checklist
- Verify the total number of shares repurchased (2,505,000) and the weighted average price paid against the company's broader buyback program limits.
- Confirm the updated share count in issue (5,907,383,837) for earnings per share calculations.
- Review the specific directors with disclosed interests (Dr. J-P Garnier, Dr. T Yamada, Mr. J D Coombe, Sir Christopher Hogg, Sir Peter Job) to ensure compliance with insider trading policies.
- Note that this filing does not contain operational or financial performance data; refer to the most recent Form 20-F or interim results for those metrics.